Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02992964 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
A Phase 1 study, sponsored by The Hospital for Sick Children.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02992964 is a Phase 1 study that was terminated before completion, run by The Hospital for Sick Children. The registered enrollment target is 11 participants.
The verdict
NCT02992964, a Phase 1 study, was terminated before completion, sponsored by The Hospital for Sick Children.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is an open-label, single arm, multi-center, pilot study of Nivolumab in pediatric patients with recurrent or refractory hypermutant malignancies aged 12 months to 18 years of age. This study is to assess clinical and radiological benefits of treatment with Nivolumab in children with hypermutated cancers, including those with bMMRD syndrome. It is our expectation that patients with bMMRD syndrome will account for the majority of patients enrolled on this study.
Interventions
- DRUG Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-05-15 |
| Est. Completion | 2023-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02992964
The ClinicalTrials.gov registry entry for NCT02992964 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Hospital for Sick Children, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nivolumab is the first listed.
NCT02992964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02992964 about?
NCT02992964 is a clinical study titled "Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers". This is an open-label, single arm, multi-center, pilot study of Nivolumab in pediatric patients with recurrent or refractory hypermutant malignancies aged 12 months to 18 years of age. This study is to assess clinical and radiological benefits of treatment with Nivolumab in children with hypermutate...
What is the current status of trial NCT02992964?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2017-05-15. Estimated completion is 2023-11-20.
What interventions are being tested in trial NCT02992964?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT02992964?
This trial is sponsored by The Hospital for Sick Children, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.